A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

NCT05672524 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Rectum
Locally Advanced Rectal Adenocarcinoma
Rectal Adenocarcinoma
HER2 Positive Rectal Adenocarcinoma
Rectal Cancer

Interventions

DRUG: Trastuzumab
DRUG: Tucatinib

Sponsor

Memorial Sloan Kettering Cancer Center